TECX
Tectonic Therapeutic, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$564.42M
P/E Ratio
—
EPS
$-4.05
Beta
—
52W High
$36.03
52W Low
$14.38
50-Day MA
$26.26
200-Day MA
$21.31
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is headquartered in Watertown, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-82.66M |
| Operating Margin | 0.00% |
| Return on Equity | -37.80% |
| Return on Assets | -25.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $13.41 |
| Price-to-Book | 2.27 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $18.78M |
| Float | $11.17M |
| % Insiders | 38.81% |
| % Institutions | 80.39% |
Historical Volatility
HV 10-Day
55.23%
HV 20-Day
50.02%
HV 30-Day
97.09%
HV 60-Day
87.69%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($78.25 target)
2
Strong Buy7
BuyData last updated: 4/9/2026